DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for extragonadal seminoma — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExtragonadal seminoma maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for extragonadal seminoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
A 34-year-old man with a 2-cm painless perineal mass underwent surgical resection; initial histology showed poorly differentiated adenocarcinoma. Local recurrence occurred three months later. After whole evaluation including ultrasound and MRI of the testes were normal, wide excision showed pure seminoma. He received two courses of bleomycin, etoposide and cisplatin (BEP) therapy, and there was no evidence of recurrence for one month. A 1983 case of bulky primary extragonadal seminoma was treated initially with chemotherapy consisting of cis-diamminedichloroplatinum and vinblastine; complete remission was documented by retroperitoneal nodal dissection. A 2022 case of a 43-year-old man with primitive extragonadal seminoma in the paravertebral dorsal region presented with a 3-month history of back pain and a 1-week history of fever. After bone marrow biopsy and exclusion of testicular seminoma, he underwent five cycles of chemotherapy; follow-up CT examinations showed reduction of the mass initially until complete remission with no evidence of recurrence.
Extragonadal germ cell tumors account for 1% to 5% of all germ cell tumors. These three case reports describe complete remissions after platinum-based chemotherapy regimens, with or without surgery. The 2006 case had only one month of follow-up after BEP therapy, so durability of that remission is not established. The 1983 case used a two-drug regimen of cisplatin and vinblastine, which is not a modern standard. The 2022 case achieved complete remission after five cycles of unspecified chemotherapy, but the abstract does not name the drugs used.
No controlled trials exist for extragonadal seminoma specifically. All evidence comes from single case reports with short follow-up. What is missing is prospective data, standardised chemotherapy protocols for this rare presentation, and any information on long-term survival or relapse rates beyond one month to three months of observation. Patient stratification by tumour site or bulk is not addressed in these reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Urologia Internationalis · 2006 · 2 citations
A Case of Primary Extragonadal Seminoma Arising in the Perineum
AbstractWe report the first case of primary extragonadal seminoma arising in the perineum. A 34-year-old-man presented with a 2-cm painless mass in the perineum. He underwent surgical resection, and histology showed poorly differentiated adenocarcinoma. Three months later, local recurrence occurred. Whole evaluation including ultrasound and MRI of the testes were normal, so he underwent surgical wide excision, and pathology showed the tumor was pure seminoma. He received two courses of bleomycin, etoposide and cisplatin (BEP) therapy, and there has been no evidence of recurrence for 1 month.
Australian and New Zealand Journal of Surgery · 1983 · 1 citations
COMPLETE REMISSION IN EXTRAGONADAL SEMINOMA PRIMARILY TREATED WITH CHEMOTHERAPY AND RESTAGED BY RETROPERITONEAL NODAL DISSECTION
AbstractA case of a bulky primary extragonadal seminoma which was treated initially with chemotherapy consisting of cis-diamminedichloroplatinum (cis-DDP) and vinblastine is reported. Previously, radiotherapy has been the initial treatment of choice for seminoma. Complete remission was documented by retroperitoneal nodal dissection.
Extragonadal germ cell tumor: A rare case in dorsal region
AbstractABSTRACT: Extragonadal germ cell tumors (GCTs) are a rare group of neoplasms that account for 1%-5% of all GCTs. These tumors can present with an unpredictable behavior and clinical manifestations depending on different factors such as histological subtype, anatomical site, and clinical stage. We report the case of a 43-year-old male patient with a primitive extragonadal seminoma located in the paravertebral dorsal region, an extremely rare site. He presented to our emergency department with a 3-month history of back pain and a 1-week history of fever of unknown origin. Imaging techniques revealed a solid tissue arising from the vertebral bodies of D9-D11 and extending in the paravertebral space. After a bone marrow biopsy and exclusion of testicular seminoma, he was diagnosed with primitive extragonadal seminoma. The patient underwent five cycles of chemotherapy, and the follow-up CT examinations showed a reduction of the mass initially till a complete remission with no evidence of recurrence.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
